D. Schiff

Publications510
h-index71
Citations17,255
Highly Influential Citations550
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • P. Wen
  • 696 Publications, 35,084 Citations
  • L. DeAngelis
  • 553 Publications, 26,448 Citations
  • D. Reardon
  • 574 Publications, 26,730 Citations
  • M. J. van den Bent
  • 339 Publications, 39,367 Citations
  • Publications
  • Influence
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
PURPOSE We evaluated the efficacy of bevacizumab, alone and in combination with irinotecan, in patients with recurrent glioblastoma in a phase II, multicenter, open-label, noncomparative trial. … Expand
  • 1,992
  • 100
  • PDF
MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes.
MicroRNA-34a (miR-34a) is a transcriptional target of p53 that is down-regulated in some cancer cell lines. We studied the expression, targets, and functional effects of miR-34a in brain tumor cells… Expand
  • 536
  • 27
  • PDF
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.
PURPOSE Our goals were to evaluate the safety of adding rituximab to methotrexate (MTX)-based chemotherapy for primary CNS lymphoma, determine whether additional cycles of induction chemotherapy… Expand
  • 302
  • 17
  • PDF
Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report.
BACKGROUND Primary intraocular lymphoma (PIOL) is an uncommon subset of primary central nervous system lymphoma. Because it is rare and difficult to diagnose, the natural history and optimal… Expand
  • 158
  • 15
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and…
PURPOSE A multicenter phase II study was conducted to assess the efficacy of rituximab, methotrexate, procarbazine, and vincristine (R-MPV) followed by consolidation reduced-dose whole-brain… Expand
  • 234
  • 11
  • PDF
Intramedullary spinal cord metastases
Our objective was to delineate clinical features and treatment outcome of patients with intramedullary spinal cord metastasis (ISCM).There are no reports of a large experience with this rare cancer… Expand
  • 188
  • 11
Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08
Purpose: Phase I: To determine the maximum tolerated doses, toxicities, and pharmacokinetics of imatinib mesylate (Gleevec) in patients with malignant gliomas taking enzyme-inducing antiepileptic… Expand
  • 398
  • 9
  • PDF
Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.
Evolving interest in meningioma, the most common primary brain tumor, has refined contemporary management of these tumors. Problematic, however, is the paucity of prospective clinical trials that… Expand
  • 255
  • 9
Malignant spinal-cord compression.
Malignant spinal-cord compression (MSCC) is a common complication of cancer and has a substantial negative effect on quality of life and survival. Despite widespread availability of good diagnostic… Expand
  • 194
  • 9
microRNA-34a is tumor suppressive in brain tumors and glioma stem cells
We recently found that microRNA-34a (miR-34a) is downregulated in human glioma tumors as compared to normal brain, and that miR-34a levels in mutant-p53 gliomas were lower than in wildtype-p53… Expand
  • 269
  • 9